IL-37b alleviates inflammation in the temporomandibular joint cartilage via IL-1R8 pathway

Ping Luo1,2,3 | Chi Feng1,2,3 | Chao Jiang1,2,3 | Xiaochun Ren1,2,3 | Liming Gou1,2,3 | Ping Ji1,2,3 | Jie Xu1,2,3

1College of Stomatology, Chongqing Medical University, Chongqing, China
2Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing, China
3Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China

Correspondence
Jie Xu and Ping Ji, Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Stomatology, Chongqing Medical University, No. 426, North Songshi Road, Yubei District, Chongqing 401147, China. Emails: xujie@hospital.cqmu.edu.cn (JX); jiping@hospital.cqmu.edu.cn (PJ)

Abstract
Objectives: Interleukin (IL)-37 is a natural suppressor of innate inflammation. This study was conducted to explore the anti-inflammatory effects of IL-37 in temporomandibular joint (TMJ) inflammation.

Materials and Methods: The expression of IL-37 in the TMJ was measured using ELISA and IHC. Human TMJ chondrocytes were treated with IL-37b and IL-1β, and inflammation-related factors were detected. siRNA-IL-1R8 was transfected into chondrocytes, and the affected pathways were detected. IL-37b was used in disc-perforation-induced TMJ inflammation in SD rats. Micro-CT, IHC, real-time PCR and histological staining were used to quantify the therapeutic effect of IL-37b.

Results: IL-37 was expressed in the synovium and the disc of patients with osteoarthritis (OA) and in the articular cartilage of condylar fracture patients. IL-37 was highly expressed in synovial fluid of patients with synovitis than in those with OA and disc displacement and was closely related to visual analogue scale (VAS) score. In vitro, IL-37b suppressed the expression of pro-inflammatory factors. In addition, IL-37b exerted anti-inflammatory effects via IL-1R8 by inhibiting the p38, ERK, JNK and NF-κB activation, while silencing IL-1R8 led to inflammation and upregulation of these signals. In disc-perforation-induced TMJ inflammation in SD rats, IL-37b suppressed inflammation and inhibited osteoclast formation to protect against TMJ.

Conclusions: IL-37b may be a novel therapeutic agent for TMJ inflammation.

1 | INTRODUCTION

The temporomandibular joint (TMJ) is a synovial joint that is frequently affected by osteoarthritis.1 Temporomandibular joint osteoarthritis (TMJOA), which is considered a prevalent chronic pain disease, leads to cartilage degeneration, subchondral bone remodelling and synovitis, thus influencing biopsychosocial conditions.2-3 Inflammation is believed to be the chief cause of pain in patients with OA, resulting from the release of pro-inflammatory cytokines.4 Increasing evidence indicates that inflammation plays a critical role in the pathogenesis of TMJOA.5,6 Condition of TMJ disc displacement without restoration (DDWoR) is mainly characterized by mouth-opening limitations.7 TMJ synovitis, the most common early-detected inflammatory arthritis, always causes joint pain, especially during acute inflammation.8 IL-1β is the major pro-inflammatory cytokine that exhibits destructive effects that are characterized by increasing cartilage degradation and suppression of cartilage matrix synthesis.9,10 Excess production of...
matrix-degrading proteases, including matrix metalloproteinases (MMPs) with disintegrin and metalloproteinase with thrombospondin motifs (ADAMTs), results from the disruption of metabolic homoeostasis and leads to cartilage degradation that occurs in inflammation. This leads to increased cleavage of aggrecan and production of collagen type I and type II molecules, which promotes cartilage destruction. There are several current treatments to relieve inflammation and prevent degradation of joint complex. However, the development of effective total joint treatments has been challenging.

Interleukin-37 (IL-37), a novel anti-inflammatory cytokine, is a newly discovered member of the IL-1 family and functions as a natural suppressor of inflammatory and immune responses. IL-37 can be induced by inflammatory stimuli such as IL-1β and LPS in PBMCs and synovial cells. Five structurally related isoforms of human IL-37 have been identified (IL-37α-e), with IL-37β being the most complete and the most reported. So far, a homologous gene for IL-37 has not been identified in mouse. However, growing evidence confirms the effects of exogenous, recombinant IL-37 on wild-type (WT) mice subjected to calcific aortic valve disease, myocardial infarction, spinal cord injury and invasive pulmonary aspergillosis. Osteoclast recruitment might be central to diseases involving bone erosion and resorption. Saeed J reported that IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in mice. IL-37 plays a crucial role in regulating inflammatory and autoimmune diseases, including liver inflammation, arthritis and allergic airway inflammation.

Despite fervent interest in IL-37, which of the variants is expressed in the chondrocytes is unknown. The mechanisms underlying the effect of IL-37 on the activation of signalling pathways remain unclear. In this study, we aimed to investigate the expressions of IL-37 variants in chondrocytes and how IL-37 might influence chondrocytes during inflammation. We focused on the effect of IL-37 on disc-perforation-induced inflammation in SD rats in vivo. This study may provide a therapeutic target for the prevention and treatment of inflammation in osteoarthritis of the TMJ.

2 MATERIALS AND METHODS

2.1 Ethical statement for human sampling

Ethical approval was obtained from the Committee of Chongqing Medical University, and informed consent was signed by all participants before sample collection. The tissue and the synovial fluid samples were collected and processed in accordance with the Declaration of Helsinki.

2.2 Patients

Twenty TMJOA patients, 15 synovitis patients and 45 DDWoR patients with informed consent were recruited from the Stomatological Hospital of Chongqing Medical University. Each patient was diagnosed with cone beam computed tomography (CBCT) or MRI and clinical parameters. Clinical data from each patient were recorded. A visual analogue scale (VAS) was used to measure pain intensity (score 0-10), with lower scores indicating lower levels of clinical symptoms or pain. Demographic and clinical information are listed in Table 1.

2.3 Sample collection and chondrocyte culture

The specimens of the synovium and disc were collected from patients with OA (n = 6), while condyles were collected from patients with condylar fracture (n = 5) for immunohistochemistry. Synovial fluid from 80 patients was collected during joint injection (20 OA, 15 synovitis and 45 DDWoR patients). The anterior part of the ear of each subject was sterilized. The upper cavity of the joint was injected with 1 mL physiological saline, and 1 mL diluent synovial fluid was extracted with no blood as described previously. The synovial fluid was centrifuged at 2000 r/min for 10 minutes. The supernatant was preserved at −80°C. These samples had undergone only one freeze-thaw cycle before the study was carried out.

For cell culture, condyles were collected from six male patients between 21-35 years old with the mean age of 28.3, with condylar fracture during surgery, and chondrocytes were immediately isolated from condylar cartilage. All cartilage specimens were washed with PBS and digested for 10 minutes in 0.25% trypsin (HyClone), followed by 1 mg/mL type I collagenase overnight. The chondrocytes were suspended in DMEM (HyClone) supplemented with 10% foetal bovine serum (HyClone) and 1% penicillin/streptomycin and cultured at 37°C in air containing 5% CO₂. After seeding the cells in the culture plates, the chondrocytes were pre-treated with human recombinant IL-37β (0.1 ng/mL; SinoBiological) for 2 hours followed by stimulation with pro-inflammatory factor IL-1β (10 ng/mL). For gene expression, samples were harvested after 24 hours; for protein expression, samples were harvested at 48 hours; and for detecting phosphorylation pathway, cells were harvested at 30 minutes.

| Characteristics | Patients with OA (n = 20) | Synovitis (n = 15) | DDWoR (n = 45) |
|-----------------|--------------------------|--------------------|----------------|
| Age (mean ± SD) | 47.650 ± 18.408          | 46.667 ± 22.908    | 43.731 ± 16.768 |
| Male/Female     | 1/19                     | 3/12               | 10/35          |
| VAS score (mean ± SD) | 5.250 ± 0.596       | 6.433 ± 0.903      | 3.000 ± 1.118  |

TABLE 1 Demographic and clinical characteristics of TMJOA, synovitis and DDWoR
2.4 | Transfection of siRNA-IL-1R8

Chondrocytes were transiently transfected with siRNA targeting IL-1R8 (GenePharma) or negative-control siRNA (scrambled; GenePharma) using GP-siRNA-mate-plus transfection reagent (GenePharma) following the manufacturer’s instructions. All experiments were performed 48 hours after transfection, and the most effective single siRNA was used for further experiments.

2.5 | Enzyme-linked immunosorbent assay (ELISA)

IL-37 was measured by conventional ELISA (Shanghai Jianglai Biotech). The method was performed according to the manufacturer’s protocol.

2.6 | Western blotting

Total protein concentration was measured using an Enhanced BCA Protein Assay Kit (Beyotime). For Western blot analysis, 30 μg of cell lysates were loaded for each sample. The proteins were transferred to PVDF membranes and blotted with antibodies for MMP1 (1:1000; Bioss), MMP9 (1:800; Zen Bioscience), MMP13 (1:1000; Abcam) and p-p38 (1:500; Zen Bioscience), p-ERK (1:1000; CST) and p-JNK (1:750; Zen Bioscience). GAPDH (1:2000; Bioss) was blotted as the loading control. Images were obtained and analysed by a computer program (Image J). Blots are representative of three separate and reproducible experiments.

2.7 | Quantitative real-time polymerase chain reaction (qRT-PCR)

The cells and tissues from TMJ were harvested and lysed in RNAiso plus (Takara). Total RNA was collected, and the total RNA was reverse-transcribed using a PrimeScript™ RT Reagent Kit with gDNA Eraser (Takara) to obtain cDNA. Next, Real-time PCR was performed on a BIORAD real-time PCR system (CFXConnect) with 40 cycles using Power TB green PCR Master Mix (Takara). GAPDH-specific primers were used as an internal control. The expression of target genes was normalized to GAPDH and was reported using 2^−ΔΔct method. The primer sequences used for qRT-PCR in this study are shown in Table 2.

2.8 | Immunofluorescence

Cells were treated with IL-1β (10 ng/mL) to induce the translocation of NF-κB into the nucleus. Meanwhile, chondrocytes were pre-treated with IL-37b (0.1 ng/mL) or transfected with siRNA-IL-1R8. After 48 hours treatment, cells were fixed with 4% paraformaldehyde and blocked with goat serum for 1 hour. Next, cells were incubated with NF-κB-p65 antibody (1:400; CST) overnight, and with goat anti-rabbit antibody (1:400; BIOSS) conjugated with Alexa Fluor 555 for 1 hour the next day. Cells were stained with DAPI. Images were acquired using Olympus microscope (Olympus).

# Table 2

| Gene  | Forward primer (5′-3′) | Reverse primer (5′-3′) |
|-------|------------------------|------------------------|
| hIL-37a | CCAAGCCCTCCCCACCATGAA | TCCAGGACCAGTACTTTTGTGATC |
| hIL-37b | CTGCTTAGAAGTGCTCAGAGGA | GCTATGAGATTCCGAGTACCT |
| hIL-37c | CCCAGTGCTGATGAGTACGTCCT | GCAGTATGAGATTCCGAGTACCT |
| hIL-37d | CCAAGCCCTCCCCACCATGAA | ACTTCTTTTTCGCGAGTACCT |
| hIL-37e | ATGCTAGCTGGTGATAGAGGG | GACCACTGGCTCTTCTACATAG |
| hIL-37f | AAACTTTTGCTGATAGAGGG | GTTGGTAATTTTGGCATACCT |
| hIL-6 | AGCGGCGGGAAGGAA | GGGAGAAGGGGCTGTTG |
| hIL-8 | AGAAGGTATTTGAGGGGCTGAA | AGTTTCATCGCACTTACCTAG |
| hMMP1 | ACTGCCAAATGGGCTTGAAG | TTCCCTTTTGAAGAAAGCAGC |
| hMMP3 | GAGGCATCACACCCCTTGGGT | TCAGAAATGGCTGACATCG |
| hMMP9 | CTTCTTGTGCTCTTTCTGGA | TGTCGCCACCCAGGTGTAAC |
| hMMP13 | ATTAAGGAGCATGCCGCTCTT | CCCAGGAGGAAAAAGCATAG |
| hAD-AMTS4 | GTCAAGCTCCACATGTCGA | GAATGCGGCCCATCTTCATC |
| hIL-18 | ATGCTAAAGTGGGGCTCCTCAACG | GCTGGCGCTTTAGGATAGA |
| hGAPDH | CTTTGGTATCGTGGAAGGACTC | GTAGAGGCAGGTAGMATC |
| rIL-1β | GCTGTGGCCAGCTACCTATGTCTTG | AGGTGCGTATCGCATCAG |
| rIL-8 | CCACTTCCAAAGTCGGGAGCTTTA | GTCATCGATCCTTTGTCACA |
| rMMP9 | AAATGGTGGGTAGCCAGCCT | TCACCCCGGGTTGGGAAC |
| rMMP13 | GTGACTTTTTCGCGAATTCCT | CAGGCCATCCACATTTGGT |
| rGAPDH | TGACCACAACACTTGTAG | GATGCAGGGATGATGTTC |
2.9 | In vivo TMJ inflammation model

All procedures and administrations for the animals were approved by Chongqing Medical University Ethics Committee and were performed according to the institutional guidelines. Sprague-Dawley rats (SD rats) were ordered from Chongqing Medical University. Male Sprague-Dawley rats (SD rats; 300-350 g) of 12 weeks old were kept in the animal facility for at least 7 days before use and received food and water ad libitum. SD rats were (n = 36 total animals) randomly divided into three groups: a sham-operated group (n = 12), model group (n = 12) and treatment group (n = 12). For TMJ disc perforation, an oblique incision was created along the zygomatic arch. Then, the TMJ superior joint space was exposed, and the disc was pulled out and perforated using a micro-ball-shaped burr with 1.5-mm diameter at the posterolateral part of TMJ disc. Then, the treatment group was treated with a volume of 50 µL human recombinant IL-37h(Sino Biological) at a dose of 20 µg/mL (twice per week). However, the disc of the sham group was not perforated. In all the groups, care was taken to prevent damage to the TMJ articular surfaces. Postoperative complications did not occur. SD rats were randomly euthanized at 1 week and 4 weeks (n = 18 for each time point) for further study. All sections of this report adhered to the ARRIVE Guidelines for reporting animal research.28

2.10 | Histological staining

TMJ samples of all animals were harvested and fixed in 4% paraformaldehyde overnight after sacrifice. After decalcification in 10% EDTA (pH 7.2-7.4), samples were embedded in paraffin and cut into 5 µm sections. Safranin O and fast green staining (Solarbio) was performed to determine proteoglycan changes, and the Osteoarthritis Research Society International (OARSI) grades were used in assessing bone destruction. The OARSI grade methods were described previously.29 Tartrate-resistant acid phosphatase (TRAP) staining was performed according to a standard protocol (Njjcbio). Only those cells showing TRAP-positive staining and comprising three or more nuclei were considered as osteoclasts. The numbers of TRAP-positive osteoclasts in the posterior and middle condylar subchondral bone were determined.

2.11 | Immunohistochemistry

Immunohistochemical (IHC) staining of IL-37 (1:250; Abcam), type I collagen (1:250; Bioss), type II collagen (1:250; Bioss), MMP1 (1:250; Bioss), MMP9 (1:250; Zen Bioscience) and MMP13 (1:250; Abcam) was performed. Sections were blocked in 10% normal goat serum, and primary antibody was incubated overnight at 4°C. The next day, HRP-conjugated secondary antibodies were used for detection after incubating the slides in 0.3% H2O2 in PBS for 15 minutes. PBS instead of the primary antibody was added to negative controls. Diaminobenzidine (DAB) was used as substrate for colour development. All slides were counterstained with haematoxylin. Images of histologically stained sections were obtained using an Olympus microscope (Olympus). An immunoreactivity scoring system was applied as described in previous studies.30 The mean optical densities of collagen I, collagen II, MMP1, MMP9 and MMP13 were obtained from the cartilage using image measurement software (IMAGE-PRO PLUS 6.0; Media Cybernetics).

2.12 | Micro-CT

The scans were performed using the following scanner settings: X-ray source voltage, 70 kVp and current 114 µA, 8 W. CT scan (SCANCO Medical AG) settings were high resolution, voxel size of 15 µm, slice thickness of 0.01 mm and FOV/diameter of 30.7 mm, with an integration time of 250 ms Micro-CT was used to assess the loss of subchondral bone. Bone volume fraction (BV/TV, %), trabecular thickness (Tb.Th, mm), trabecular number (Tb.N, 1/mm) and trabecular separation (Tb.Sp, mm) of TMJ subchondral bone were analysed. The height of the joint, measuring from the highest point of absorption of the joint to the neck of the condyle, was used to evaluate the degree of articular cartilage degradation.

2.13 | Statistical analysis

All quantitative data are expressed as the mean ± SD unless otherwise indicated. Statistical analyses were performed with sPS 19.0 (IBM Corporation). Pearson's correlation coefficient was used to assess the correlation of IL-37 in the synovial fluid with VAS score. The rest of the values are expressed as means ± SD. Data were examined for normality by skewness/kurtosis. Transforming a non-normal distribution into a normal distribution was performed using Blom's formula.31 Significant differences in the results were determined by one-way ANOVA with Tukey test. A P value < .05 was considered statistically significant. Ns indicates no significant difference. P < .05, P < .01, P < .001 and P < .0001 in figures were represented as *, ** ***, and ****, respectively.

3 | RESULTS

3.1 | IL-37 protein level is positively correlated with TMJ inflammation

To analyse the involvement of IL-37 in human TMJ, the expression of IL-37 in human inflammatory TMJ was first examined using immunohistochemistry (Figure 1A). IL-37 was expressed in the inflammatory articular disc, the cartilage and the synovium of patients. IL-37 was mainly localized in the nucleus and could be observed in the membranes, cytoplasm and extracellular matrix of TMJ cells. Patients with active TMJ synovitis showed higher IL-37 level than OA and non-acute inflammatory DDWoR patients (Figure 1B). As shown in Figure 1C, IL-37 level in synovial fluid was positively correlated with VAS score (r = .5896, P < .0001).

3.2 | IL-37b suppresses IL-1β-induced expression of related genes in chondrocytes

To examine which variants of IL-37 are expressed in the chondrocytes, RT-PCR was performed to measure IL-37a-e mRNA
expression levels in the chondrocytes. Condylar chondrocytes produced higher levels of IL-37a and b mRNAs but tiny amount of IL-37c, d and -e mRNAs (Figure 2A). Next, to determine the anti-inflammatory effect of IL-37b, chondrocytes were pre-treated with recombinant IL-37b for 2 hours, followed by IL-1β stimulation. IL-37b significantly alleviated IL-1β-induced inflammatory gene expression of IL-6, IL-8, MMP1, MMP3, MMP9, MMP13 and ADAMTS4 (Figure 2B). Similar results were
obtained for protein analysis of MMP1, MMP9 and MMP13 (Figure 2C).

3.3 Attenuation of IL-37 activity in silencing IL-1R8

To explore whether IL-37b recruits IL-1R8 for exerting anti-inflammatory effects, IL-1R8-specific siRNA was constructed to knock-down IL-1R8 gene in vitro. qRT-PCR indicated that chondrocytes transfected with siRNAs had decreased expression of IL-1R8 compared to the controls (scrambled; Figure 3A). After pre-treatment with IL-37b for 2 hours and stimulation with IL-1β, the abundance of pro-inflammatory IL-6 (~65%) and IL-8 (~58%) was diminished. In the absence of IL-1R8, the anti-inflammatory effect of IL-37b was obviously weaker, the decrease in IL-6 level was only 17% (in contrast to the 65% noted above) and that in IL-8 was 10% (in contrast to the 58% noted above; Figure 3B).

3.4 Recombinant IL-37b inhibits p38, JNK, ERK and NF-κB p65 activation in response to IL-1β association with IL1R8

To further explore the possible effect of IL-37b-IL-1R8 complex on MAPK pathway, the lysates in the phospho-kinase array were assessed by Western blotting. As shown in Figure 3C and Figure 3D, exposure to IL-1β increased p-ERK, p-p38 and p-JNK levels compared to those in non-stimulated cells. However, in IL-37-pre-treated cells, p-ERK, p-p38 and p-JNK levels were significantly attenuated. After silencing IL-1R8 in the chondrocytes, levels of these signals were significantly reactivated. Next, the activation of NF-κB p65 was measured via immunofluorescence. As shown in Figure 3E, cells were treated with IL-1β to induce NF-κB p65 translocation from the cytoplasm to the nucleus. Pre-treatment with IL-37b inhibited the translocation of NF-κB into the nucleus; however, silencing IL-1R8 resulted in failure to inhibit the translocation of NF-κB into the nucleus.

3.5 IL-37b alleviates condyle degradation in disc-perforated TMJ

To further assess the contribution of IL-37b to anti-inflammatory functions in vivo, a disc-perforation-induced inflammation model was established in SD rats (4A). Macroscopic analysis showed that the size of disc perforation in model group was larger, while the size of disc perforation in the IL-37b-treated group was smaller than that in the model group. In addition, there was a significant difference in macroscopic tissue reactions, amelioration of inflammation, swelling and hyperplasia between IL-37b-treated group and model group at all tested time points. Moreover, cartilage became significantly thinner and flatter after surgery, while IL-37b-treated group showed less change in the cartilage than the control group (Figure 4B). As shown in Figure 4C, we observed that the height of the condyle in the treatment group increased compared to the model group. The articular cartilage improvement in IL-37b group was further confirmed in the histological assessment. Histopathological evidence showed that, compared to model group, the treatment group exhibited less cartilage damage and condyle...
erosion. In the model group, proteoglycan loss was remarkably observed with Safranin O, showing greatly reduced cartilage staining. In contrast, IL-37b-treated rats showed limited proteoglycan loss (Figure 4D). The inflammation-induced cartilage destruction was evaluated using the modified OARSI grade system. The OARSI grade of IL-37b treatment group was lower than that of the model group, and the normal group showed no cartilage destruction (OARSI grade 0; Figure 4E). To detect cartilage matrix loss, type I collagen (COL I) and type II collagen (COL II) were stained by immunohistochemistry, which showed that the treatment group had
more expression of Col I and Col II in the cartilage layer compared to the model group (Figure 4F). In addition, immunohistochemistry showed significantly upregulated MMP1, MMP9 and MMP13 in the cartilage layer of the model group, while in IL-37b treated group, there was significant downregulation of these inflammatory proteins (Figure 5A). Similarly, IL-37b significantly reduced mRNA levels of pro-inflammatory molecules IL-1β, IL-6, MMP9 and MMP13 (Figure 5B).

3.6 | IL-37b reduces subchondral bone loss in disc-perforated TMJ

Micro-CT was used to evaluate the changes in the microarchitecture of TMJ subchondral bone. Figure 6A showed that the model group had a lower bone volume fraction (BV/TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N) than the control group. However, IL-37b-treated group showed a statistically significant increase in BV/TV, Tb.Th and Tb.N in subchondral trabecular bone compared to the model group. However, trabecular separation (Tb.Sp) in the model group was higher than that in the control group and significantly lower in IL-37-treated group than in the model group. The three-dimensional images showed subchondral bone loss, and the treatment group showed significantly less subchondral bone loss than the model group, while the control TMJ maintained subchondral bone integrity (Figure 6B). In addition, the number of tartrate-resistant acid phosphatase (TRAP)-positive cells, as a biomarker for bone resorption in the subchondral bone was significantly decreased in IL-37b-treated rats (Figure 6C).

4 | DISCUSSION

Osteoarthritis is the most common joint disease in the world, but there is no standard treatment to prevent OA progression. However, increasing evidence shows that inflammation plays a critical role in OA pathology, suggesting that targeting inflammation in OA could be a promising strategy. IL-37 has emerged as a fundamental inhibitor of the innate immune response, attenuating inflammation in models of periodontal inflammation, gout and colitis. However, no study has investigated the effect of IL-37 on TMJ inflammation. Based on these findings, we investigated whether and how IL-37 downregulates TMJ inflammation.

First, to analyse the involvement of IL-37 in human TMJ inflammation, our data revealed that IL-37 was expressed in the inflamed
disc and synovium of patients with TMJOA and condyle cartilage in condylar fracture. In the synovial fluid, IL-37 was highly expressed in active inflammation in patients with synovitis than in those with OA and DDWOR. Unfortunately, for ethical reasons, healthy individuals were not included. In addition, significant positive correlations were observed between synovial fluid IL-37 level and clinical VAS score.

Next, we studied the anti-inflammatory properties of the recombinant human IL-37b in TMJ chondrocytes in vitro. IL-37 possesses five different isoforms (named IL-37a–e). However, which isoform is expressed in the TMJ chondrocytes remains unknown. Interestingly, our study suggested that IL-37a and IL-37b were highly expressed in the chondrocytes. It has been reported that IL-37b being the most functional complete of these isoforms, and the anti-inflammatory effect was the most widely reported. In addition, IL-37b was the most abundant in the chondrocytes, so we focused on this isoform. Recombinant IL-37b inhibited the expression of inflammatory cytokines, such as IL-6, IL-8, MMPs and ADAMTS4, in IL-1β-induced inflammation in vitro, consistent with previously published study.

To explore the specific mechanism of action of IL-37b in inflammation, it was important to know the mechanism through which receptor complex IL-37b works. IL-37b can bind to IL-1R8 to involve in allergic airway inflammation, asthma and atherosclerosis. Therefore, we hypothesized that IL-1R8 is required for IL-37b to downregulate inflammation in TMJ. Here, IL-1R8 was knocked-down and assessed by qRT-PCR. This clearly demonstrated that the absence of IL-1R8 almost completely abolished IL-37b protection against IL-1β-induced inflammation. IL-1β is the major pro-inflammatory cytokine implicated in TMJOA, and it activates the signalling cascade involving NF-κB and the cascades involving the terminal MAPKs JNK, p38 and ERK. It has been reported that IL-37 suppresses LPS-induced inflammation in macrophages by downregulating JNK, p38 and ERK signalling pathways. In addition, some reports showed that IL-37 inhibited inflammation by inhibiting NF-κB activation. Our data revealed that in the chondrocytes, IL-37b downregulated ERK, JNK and p38 MAPK signals and inhibited NF-κB translocation into the nucleus after IL-1β stimulation. In contrast, silencing IL-1R8 led to inflammation upregulation by enhancing these signals. These results indicate that IL-37b inhibits p38, JNK, ERK and NF-κB P65 activation in response to IL-1β association with IL1R8 to inhibit inflammation. Summarily, these results suggest that local expression of IL-37b contributes directly to the suppression of joint inflammation in TMJ and that IL-37 requires IL-1R8 to reduce inflammation by downregulating MAPK signals. These findings show that IL-37b can be considered for treatment strategies in patients with TMJ inflammation.

The in vivo model of rat articular disc perforation showed that human recombinant IL-37b protein reduced the expression of inflammatory factors and dampened the pathological process of inflammation in TMJ. Discectomy results showed OA-like changes in rat TMJ, and the same effect has been verified in rabbit joint disc perforation study. Sustained inflammation induces structural abnormalities in the TMJ. In our study, flattening of condyles, erosion and sclerosis were observed in the model group. The height of the condyle was more reduced in the model group than the treatment group, indicating that IL-37b protected the joint and reduced bone destruction. Collagen constitutes a major proportion of the extracellular matrix (ECM) in the cartilage, and the degradation of the ECM is done mainly by MMPs. Therefore, to visualize proteoglycans and collagen protein changes in cartilage, the collagen content of condyles was measured by IHC and Safranin O and fast green staining, and the results showed that the collagen content in IL-37b treatment group was higher than that in the model group. The inflammatory factors IL-1β, IL-6 and MMPs were significantly reduced in IL-37b compared to the model group. Our in vivo results further indicated that IL-37b had potent anti-inflammatory effects and protected against TMJ inflammation by reducing collagen degradation and matrix metalloenzymes (MMPs). The production of osteoclasts is one of the important pathological features of inflammatory bone destruction. Severe inflammatory bone destruction is closely related to bone metabolism disorders. In our study, IL-37b suppressed osteoclast formation. Tartrate-resistant acid phosphatase (TRAP) staining showed that the positive cells in the treatment group were significantly fewer than that in the model group. This finding is consistent with that of micro-CT, which indicated that L-37b protected against subchondral bone loss in vivo. These results suggest that IL-37b inhibits excessive inflammation in the TMJ and reduces joint destruction.

In conclusion, we demonstrated the therapeutic potential of the novel anti-inflammatory cytokine IL-37b in the treatment of inflammation of the TMJ. IL-1R8 is required for IL-37b to exert anti-inflammatory effects in the TMJ. IL-1R8 silencing impaired the activity of IL-37b and upregulated inflammatory factors. Disc-perforation-induced inflammation revealed the anti-inflammatory and condyle-protective ability of IL-37. These results suggest that targeting IL-37 pathway may provide a new therapeutic strategy for treating human TMJ inflammation.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

ORCID
Jie Xu https://orcid.org/0000-0003-2435-0382

REFERENCES
1. Abrahamsson AK, Kristensen M, Arvidsson LZ, Kvien TK, Larheim TA, Haugen IK. Frequency of temporomandibular joint osteoarthritis and related symptoms in a hand osteoarthritis cohort. Osteoarthr Cartil. 2017;25:654-657.
2. Slade GD, Ohrbach R, Greenspan JD, et al. Painful temporomandibular disorder: Decade of discovery from opera studies. J Dent Res. 2016;95(10):1084-1092.

3. Nitzan DW, Svidovsky J, Zini A, Zadik Y. Effect of arthrocentesis on symptomatic osteoarthritis of the temporomandibular joint and analysis of the effect of preoperative clinical and radiologic features. J Oral Maxillofac Surg. 2017;75(2):260-267.

4. Wang XD, Zhang JN, Gan YH, Zhou YH. Current understanding of pathogenesis and treatment of TMJ osteoarthritis. J Dent Res. 2015;94(5):666-673.

5. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis. Current understanding. Immunol Lett. 2002;110(10):1419-1427.

6. Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis - chondrocytes in focus. Cell Signal. 2018;53:212-223.

7. Wang XD, Kou XX, Mao JJ, Gan YH, Zhou YH. Sustained inflammation induces degeneration of the temporomandibular joint. J Dent Res. 2012;91(5):499-505.

8. van Meurs JB, van Lent PL, van de Loo AA, et al. Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis. Ann Rheum Dis. 1999;58(6):350-356.

9. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev. 2018;281(1):179-190.

10. Ding LP, Hong XP, Sun BD, et al. IL-37 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells. Sci Rep. 2017;7(1):11601.

11. van Meurs JB, van Lent PL, Van de Loo AA, et al. Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis. Ann Rheum Dis. 1999;58(6):350-356.

12. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev. 2018;281(1):179-190.

13. Zeng Q, Song R, Fullerton DA, et al. Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proc Natl Acad Sci U S A. 2017;114(7):1631-1636.

14. Zhi R, Sun H, Yu K, et al. Interleukin-37 and dendritic cells treated with interleukin-37 plus troponin ameliorate cardiac remodeling after myocardial infarction. J Am Heart Assoc. 2016;5(12):e004406.

15. Coll-Miro M, Francos-Quijorna I, Santos-Nogueira E, et al. Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2016;113(5):1411-1416.

16. Moretti S, Bozza S, Okonomou V, et al. IL-37 inhibits inflammation, activation and disease severity in murine aspergillosis. PLoS Pathog. 2014;10(11):e1004462.

17. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for tnf-alpha-mediated joint destruction. J Clin Invest. 2002;110(10):1419-1427.

18. Saeed J, Kitaura H, Kimura K, et al. IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo. Immunol Lett. 2016;175:8-15.

19. Sakai N, Van Sweringen HL, Belzaire RM, et al. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol. 2012;27(10):1609-1616.

20. Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2017;56(12):2256.

21. Lunding L, Wezering S, Vock C, et al. IL-37 requires IL-18R alpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy. 2015;70(4):366-373.

22. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007-1019.

23. Wei L, Xiong H, Li B, Cheng Y, Long X. Boundary-lubricating ability and lubricin in synovial fluid of patients with temporomandibular joint disorders. J Oral Maxillofac Surg. 2010;68(10):2478-2483.

24. Kilkenny C, Browne WI, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthr Cartil. 2012;20:256-260.

25. Moskowitz RW. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthr Cartil. 2006;14(1):1-2.

26. Wang CJ, Zhou ZG, Holmqvist A, et al. Survivin expression quantified by Image Pro-Plus compared with visual assessment. Appl Immunohistochem Mol Morphol. 2009;17:530-535.

27. Blom G. Statistical estimates and transformed beta-variables. New York, NY: Wiley; 1958.

28. Ofenbacher S, Jiao Y, Kim SJ, et al. GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat Commun. 2018;9:3686.

29. Liu L, Xue Y, Zhu Y, et al. Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout. Arthritis Res Ther. 2016;18:268.

30. McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A. 2011;108(40):16711-16716.

31. Zhang L, Zhang J, Gao P. The potential of interleukin-37 as an effective therapeutic agent in asthma. Respir Res. 2017;18(1):192.

32. Ly J, Xiong Y, Li W, et al. IL-37 inhibits IL-4/IL-13-induced cc11 production and lung eosinophilia in murine allergic asthma. Allergy. 2018;73(8):1642-1652.

33. Yang Z, Kang L, Wang Y, et al. Role of IL-37 in cardiovascular disease inflammation. Can J Cardiol. 2019;35:923-930.

34. Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci USA. 2015;112:2497-2502.

35. Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-1Rα and IL-1Rβ to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16(4):354-365.

36. Meng P, Chen ZG, Zhang TT, et al. IL-37 alleviates house dust mite-induced chronic allergic asthma by targeting TSLP through the NF-κB and ERK1/2 signaling pathways. Immuno Cell Biol. 2019;97:403-415.

37. Cohen WA, Servais JM, Polur I, Xu L. Articular cartilage degeneration in the contralateral non-surgical temporomandibular joint in mice with a unilateral partial discectomy. J Oral Pathol Med. 2014;43(2):162-165.

38. Embree MC, Iwaoa GM, Kong D, et al. Soft tissue ossification and condylar cartilage degeneration following tmj disc perforation in a rabbit pilot study. Osteoarthr Cartil. 2015;23(4):629-639.

39. Chu WC, Zhang S, Sng TJ, et al. Distribution of pericellular matrix molecules in the temporomandibular joint and their chondroprotective effects against inflammation. Int J Oral Sci. 2017;9:43-52.

40. Penock AT, Robertson CM, Emmerson BC, Harwood FL, Amiel D. Role of apoptotic and matrix-degrading genes in articular cartilage and meniscus of mature and aged rabbits during development of osteoarthritis. Arthritis Rheum. 2007;56(5):1529-1536.
45. Seeling M, Hillenhoff U, David JP, et al. Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A. 2013;110:10729-10734.

46. Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5(3):4711.

47. Tang R, Yi J, Yang J, et al. Interleukin-37 inhibits osteoclastogenesis and alleviates inflammatory bone destruction. J Cell Physiol. 2019;234:7645-7658.

How to cite this article: Luo P, Feng C, Jiang C, et al. IL-37b alleviates inflammation in the temporomandibular joint cartilage via IL-1R8 pathway. Cell Prolif. 2019;52:e12692. https://doi.org/10.1111/cpr.12692